Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 1001-1008

  Altavilla, Amelia ^a   Iacovelli, Roberto ^a   Procopio, Giuseppe ^b   Alesini, Daniele ^a   Risi, Emanuela ^a   Campennì, Giuseppe Maria ^a   Palazzo, Antonella ^a   Cortesi, Enrico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Abiraterone acetate; Antiangiogenic therapy; Cabazitaxel; Chemotherapy; CRPC; Hormone therapy; MDV3100; Second line therapy; Sipuleucel T; TAK 700

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; BEVACIZUMAB; CABAZITAXEL; CEDIRANIB; DEXAMETHASONE; DOCETAXEL; GONADORELIN AGONIST; KETOCONAZOLE; MITOXANTRONE; ORTERONEL; PLACEBO; PLATINUM; PREDNISONE; SATRAPLATIN; SIPULEUCEL T; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; TAXOID;

ADD ON THERAPY; ANEMIA; ANOREXIA; ANTIANDROGEN THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER FUNCTION TEST; MULTIMODALITY CANCER THERAPY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; DRUG RESISTANCE; IMMUNOTHERAPY; MALE; METHODOLOGY; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE TUMOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84865836886     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21188     Document Type: Review

References (52)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46:765-81; PMID:20116997; http://dx.doi.org/10.1016/j.ejca.2009.12.014.
2. Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009; 21:260-5; PMID:19363343; http://dx.doi.org/10. 1097/CCO.0b013e32832a1868.
3. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-13; PMID:10561316.
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J ClinOncol 1996; 14:1756-64; PMID:8656243.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12; PMID:15470213; http://dx.doi.org/10.1056/NEJMoa040720.
6. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242-5; PMID:18182665; http://dx.doi.org/10.1200/JCO.2007.12.4008.
7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20; PMID:15470214; http://dx.doi.org/10.1056/NEJMoa041318.
8. Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26:5261-8; PMID:18794543; http://dx.doi.org/10.1200/JCO.2008. 16.9524.
9. McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997; 15:2691-700; PMID:9215842.
10. Latif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005; 23:79-84; PMID:15528984; http://dx.doi.org/10. 1023/B:DRUG.0000047109.76766.84.
11. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, et al.; Genitourinary Tract Group of the EORTC. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68:2-9; PMID:15741753; http://dx.doi.org/10.1159/000084201.
12. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27:5431-8; PMID:19805692; http://dx.doi.org/10.1200/JCO.2008.20.1228.
13. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723-30; PMID:19147780; http://dx.doi.org/10. 1158/1078-0432.CCR-08-0596.
14. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al.; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-54; PMID:20888992; http://dx.doi.org/10.1016/S0140-6736(10)61389-X.
15. Pivot X, Koralewski P, Hidalgo JL, Chan A, Gonçalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547-52; PMID:18436520; http://dx.doi.org/10.1093/ annonc/mdn171.
16. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004; 61:332-53; PMID:15389811; http://dx.doi.org/10.1002/pros.20115.
17. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46:142-8; PMID:7624983; http://dx.doi.org/ 10.1016/S0090-4295(99)80182-4.
18. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10:981-91; PMID:19796750; http://dx.doi.org/10.1016/S1470-2045(09)70229- 3.
19. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27:36-41; PMID:19111796; http://dx.doi.org/ 10.1016/j.urolonc.2008.03.021.
20. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994; 50:267-73; PMID:7918112; http://dx.doi.org/10.1016/0960-0760(94)90131-7.
21. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-71; PMID:18645193; http://dx.doi.org/10.1200/ JCO.2007.15.9749.
22. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-8; PMID:20159824; http://dx.doi.org/10.1200/JCO.2009.24.1281.
23. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-8; PMID:19470933; http://dx.doi.org/10.1200/JCO.2008.20.0642.
24. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-95; PMID:20159823; http://dx.doi.org/10. 1200/JCO.2009.24.6819.
25. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28:1496-501; PMID:20159814; http://dx.doi.org/10.1200/JCO.2009.25. 9259.
26. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al.; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005; PMID:21612468; http://dx.doi.org/10.1056/NEJMoa1014618.
27. Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer 2003; 98:1855-62; PMID:14584067; http://dx.doi.org/10.1002/cncr.11733.
28. Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, et al. A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol 2010; 183:2219-26; PMID:20399458; http://dx.doi.org/10.1016/j.juro.2010.02.020.
29. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation anti-androgen for treatment of advanced prostate cancer. Science 2009; 324:787-90; PMID:19359544; http://dx.doi.org/10.1126/science. 1168175.
30. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al.; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-46; PMID:20398925; http://dx.doi.org/10.1016/S0140-6736(10)60172-9.
31. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 2012; 30; PMID:22547597.
32. Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D, Stadler WM. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study. J Clin Oncol 2010; 28.
33. Agus DB, Stadler WM, Shevrin DH, Hart L, Mac Vicar GR, Hamid O, et al. Safety, efficacy, and pharmacodynamics of the investigational agent ortonel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study. J Clin Oncol 2012; 30.
34. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol 2006; 24:250-3; PMID:16678059; http://dx.doi.org/10.1016/j.urolonc.2005.11.021.
35. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143:401-9; PMID:7688183.
36. Strohmeyer D, Rössing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000; 42:26-33; PMID:10579796; http://dx.doi.org/10.1002/(SICI)1097-0045(20000101)42:1〈26:: AIDPROS4〉3.0.CO;2-6.
37. Ullén A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, et al. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol 2010; 37:15-20; PMID:20514392; http://dx.doi.org/10.3892/ijo-00000648.
38. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14:209-14; PMID:18172272; http://dx.doi.org/10.1158/1078- 0432.CCR-07-1355.
39. Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007; 97:1480-5; PMID:18040273; http://dx.doi.org/10.1038/sj.bjc.6604064.
40. Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2007; 19:746-51; PMID:18056648; http://dx.doi.org/10. 1093/annonc/mdm554.
41. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008; 270:229-33; PMID:18586384; http://dx.doi.org/10.1016/j.canlet.2008.05.007.
42. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-37; PMID:12538485.
43. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21:319-24; PMID:19633050; http://dx.doi.org/10.1093/annonc/mdp323.
44. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 2010; 28.
45. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54:1089-1096; PMID:18276061; http://dx.doi.org/10.1016/j.eururo.2008.01.082.
46. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
47. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59:572-83; PMID:21315502; http://dx.doi.org/10.1016/j.eururo.2011.01.025.
48. Loriot Y, Massard C, Albiges L, Di Palma M, Blanchard P, Bossi A, et al. Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity. J Clin Oncol 2012; 30.
49. Collette L, Burzykowski T, Schröder FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006; 42:1344-50; PMID:16730974; http://dx.doi.org/10.1016/j.ejca.2006.02.011.
50. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-9; PMID:18829513; http://dx.doi.org/10.1158/1078-0432.CCR-08-0872.
51. Scher HI, Heller G, Molina A, Kheoh TS, Attard G, Moreira J, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011; 29.
52. Iacovelli R, Palazzo A, Procopio G, Gazzaniga P, Cortesi E. Abiraterone acetate in castration-resistant prostate cancer. Anticancer Drugs 2011; PMID:22123334.